We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Fellowships
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Board Certifications
Internal Medicine; Hematology
I am a board-certified hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center.
My clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. My patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with my patients and their referring providers to personalize decision-making and monitoring given the chronic nature of the disorders I treat.
Read more
Before joining Memorial Sloan Kettering, I was on the faculty of Oregon Health and Sciences University for 13 years. There I directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML from imatinib (Gleevec) onwards. I completed both residency and fellowship training at the NewYork-Presbyterian Hospital / Weill Cornell Medical College in Manhattan.
The treatment of myeloproliferative neoplasms (MPNs), especially CML, has seen unprecedented advance in the last 15 years. Development and approval of a number of targeted ‘kinase inhibitor’ therapies has led to the realization of long-term treatment success and a potential functional cure for CML and discovery of therapeutic targets in other MPNs. Careful decision-making is very important from diagnosis onward in MPNs given the array of options and potential for novel approaches. Areas of clinical focus for me include early optimization of therapy, understanding the basis and management of emerging side effects and managing resistance and intolerance to therapy.
Memorial Sloan Kettering has significant expertise in the molecular characterization of MPNs and a distinguished history in the development of cutting-edge effective therapies for a wide variety of leukemias. The MPN program within the Leukemia Service at Memorial Sloan Kettering Cancer Center is in an excellent position to continue research into the optimization of CML therapy and to develop new and better treatments for MPNs broadly. We have a group of clinicians focused on MPNs and an expanding clinical trials program to answer key questions and the program is dedicated to bring our patients novel therapies, best monitoring practices and long-term treatment success.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Mauro’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael J. Mauro discloses the following relationships and financial interests:
AbbVie Provision of Services
Bristol-Myers Squibb Provision of Services
Novartis Pharmaceuticals Corporation Provision of Services
Pfizer, Inc. Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
